Product Datasheet
LATS1/2 (Phospho-Thr1079/1041) Antibody
Catalog Number: 11736
Technical:tech@swbio.com
Information:info@swbio.com
Description
- Swiss-Prot No.:
- Swiss-Prot#: O95835/Q9NRM7;
NCBI Gene#: 9113/26524;
NCBI Protein#: NP_004681.1.
- Form of Antibody:
- Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
- Storage:
- Store at -20˚C/1 year
- Immunogen:
- Peptide sequence around phosphorylation site of threonine 1079/1041 (E-F-T(p)-F-R) derived from Human LATS1/2 .
- other_names:
- WARTS; Large tumor suppressor 1; EC 2.7.11.1;
- Purification:
- Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
- Specificity:
- The antibody detects endogenous levels of LATS1/2 only when phosphorylated at threonine 1079/1041.
- Background:
The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding.
Tao W., Nat. Genet. 21:177-181(1999).
Nishiyama Y., FEBS Lett. 459:159-165(1999).
The MGC Project Team, Genome Res. 14:2121-2127(2004).
© Signalway Biotechnology All Rights Reserved.